- |||||||||| Journal, Metastases: IMPACT OF SYSTEMIC TREATMENTS FOR ADVANCED THYROID CANCER ON THE ADRENAL CORTEX. (Pubmed Central) - May 9, 2024
Our data confirm that systemic treatments for advanced thyroid cancer can lead to an impaired cortisol secretion. A reduction in the other hormones secreted by the adrenal cortex has been firstly reported and should be considered in the more appropriate management of these fragile patients.
- |||||||||| Halaven (eribulin mesylate) / Eisai, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion, Metastases: Eribulin and Lenvatinib in Advanced Solid Tumors (clinicaltrials.gov) - May 9, 2024 P2, N=29, Completed, A reduction in the other hormones secreted by the adrenal cortex has been firstly reported and should be considered in the more appropriate management of these fragile patients. Unknown status --> Completed
- |||||||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment open: Triple vs. Dual Adjuvant Therapy Following Liver Resection for HCC. (clinicaltrials.gov) - May 7, 2024 P4, N=300, Recruiting, The current study reinforces the clinical effectiveness of first line lenvatinib as standard of care in patients with RAI-R DTC in real-world clinical practice in the US. Not yet recruiting --> Recruiting
- |||||||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Review, Journal: Lenvatinib in hepatocellular carcinoma: Resistance mechanisms and strategies for improved efficacy. (Pubmed Central) - May 3, 2024 The results suggest that abnormal activation of pathways, drug transport, epigenetics, tumour microenvironment, cancer stem cells, regulated cell death, epithelial-mesenchymal transition, and other mechanisms are involved in the development of lenvatinib resistance in HCC and subsequent HCC progression. To improve the therapeutic outcomes of lenvatinib, inhibiting acquired resistance, combined therapies, and nano-delivery carriers may be possible approaches.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
P2 data, Journal, Metastases: Phase II study of pembrolizumab and lenvatinib in advanced well-differentiated neuroendocrine tumors. (Pubmed Central) - May 2, 2024 To improve the therapeutic outcomes of lenvatinib, inhibiting acquired resistance, combined therapies, and nano-delivery carriers may be possible approaches. The combination of pembrolizumab and lenvatinib did not show sufficient response in patients with NETs to warrant continued enrollment on trial.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Welireg (belzutifan) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Trial primary completion date: LITESPARK-016: Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016) (clinicaltrials.gov) - Apr 28, 2024 P2, N=730, Recruiting, Tislelizumab plus lenvatinib demonstrated promising antitumor activity with favourable tolerability as first-line therapy for patients with uHCC. Trial completion date: Aug 2026 --> Mar 2027 | Trial primary completion date: Aug 2026 --> Mar 2027
- |||||||||| Review, Journal: Combination immune checkpoint and targeted protein kinase inhibitors for the treatment of renal cell carcinomas. (Pubmed Central) - Apr 28, 2024
Other combination therapies include pembrolizumab (targeting programed cell death protein 1) and axitinib (a VEGFR and PDGFR blocker) or lenvatinib (a multikinase inhibitor). Since the KEYNOTE-426 clinical trial, the use of immune checkpoint inhibitors in combination with protein-tyrosine kinase inhibitors is now the standard of care for most patients with metastatic renal cell carcinomas and monotherapies are used only in those individuals who cannot receive or tolerate immune checkpoint inhibitors.
- |||||||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: Predictive insights into plant-based compounds as fibroblast growth factor receptor 1 inhibitors: a combined molecular docking and dynamics simulation study. (Pubmed Central) - Apr 26, 2024 To gain further insights into the conformational dynamics of Mundulone and the reference FGFR1 inhibitor, Lenvatinib, we conducted time-evolution analyses employing 200?ns molecular dynamics simulations (MDS) and essential dynamics...Overall, the findings indicate that Mundulone exhibits promising binding affinity, specific interactions, and favorable drug profiles, making it a promising lead candidate. Further experimental analysis will be necessary to confirm its effectiveness and safety profiles for therapeutic advancement in the cancer field.Communicated by Ramaswamy H. Sarma.
- |||||||||| Kaitanni (cadonilimab) / Akesobio
Trial completion, Enrollment change, Trial primary completion date, Combination therapy, Metastases: AK104-206: A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Plus Lenvatinib in First-line Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - Apr 25, 2024 P1/2, N=59, Completed, In particular, LEN + ICI, with or without LRT, appears to represent a highly effective conversion regimen, with an acceptable conversion rate and well-characterized safety profile. Recruiting --> Completed | N=30 --> 59 | Trial primary completion date: Apr 2023 --> Nov 2023
- |||||||||| Zepsun (donafenib) / Suzhou Zelgen, Stivarga (regorafenib) / Bayer, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Comparative efficacy of systemic sequential regorafenib after TACE combined with first-line targeted drugs (donafenib, sorafenib, or lenvatinib) after treatment failure for advanced hepatocellular carcinoma: A retrospective, single-center, real-world study. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6910; This retrospective, single-center, real-world study demonstrated that when donafenib failed the regorafenib could still improve the prognosis of advanced HCC pts with fewer AEs. The study will continue to focus on overall survival(OS) and whether combined ICIs or not in the 1st-line/ 2nd-line treatment could have a positive effect on OS.
|